Entourage Health: A Quarter of Growth and Innovation

Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE) has reported robust financial results for the third quarter of 2024, reflecting the company's strategic focus and adaptability in the competitive cannabis industry. With total revenue reaching $13.6 million, a 11% increase year-over-year, Entourage has demonstrated its commitment to delivering meaningful and timely offerings to its customers and patients.

The company's strong performance can be attributed to its strategic shift into different markets, allowing for diversification and tapping into new opportunities. The launch of the Dime Bag value brand, for instance, has helped Entourage address evolving consumer needs and expand into new segments. This initiative, combined with increased operational efficiencies, has resulted in a 9% increase in net revenue for the quarter.

Entourage's inventory management and product mix optimization have also contributed to its improved financial performance. The company's inventory and biological assets, as of September 30, 2024, stood at $10.951 million, a $940k increase from December 31, 2023 ($10.010 million). This growth indicates a strategic focus on maintaining a balanced inventory to meet demand and maximize profit margins. Additionally, Entourage's gross margin before changes in fair value improved to 30% in Q3 2024, up from 27% in Q3 2023, demonstrating the success of its product mix optimization strategies.



The company's operational efficiency improvements, such as advancements in pre-roll automation, have significantly contributed to its strong third quarter 2024 financial results. Gross profit margins rose to 30% in Q3 2024, up from 27% in Q3 2023, driven by increased operational efficiencies. This incremental improvement is attributed to advancements in pre-roll automation, product mix optimization, and packaging improvements, which lowered direct labour costs and improved margins. Consequently, EBITDA improved by 70% for the quarter and 65% year-over-year, reflecting the Company's progress toward profitability.



Entourage Health's dedication to creating innovative cannabis products tailored to customer preferences has significantly contributed to its financial success. In Q3 2024, the Company reported a 11% year-over-year increase in total revenue, reaching $13.6 million. This growth can be attributed to the Company's strategic shift into different markets, allowing it to diversify and tap into new opportunities. Gross profit before changes in fair value also improved by 21% year-over-year to $2.9 million, driven by operational efficiencies from advancements in pre-roll automation, product mix optimization, and packaging improvements. Subsequently, gross margins rose to 30%, up from 27% in Q3 2023, reflecting the Company's commitment to delivering meaningful and timely offerings to its customers and patients.

In conclusion, Entourage Health's strong third quarter 2024 financial results demonstrate the company's resilience and adaptability in the face of market changes. By focusing on strategic market segmentation, product offerings, and operational efficiency, Entourage has been able to achieve significant growth and improve its financial performance. As the company continues to innovate and address evolving consumer needs, investors can expect more positive developments in the future.
*